Testing a new blood cancer drug alone or combined with existing treatments

This trial is testing a new investigational drug called surzetoclax for people with multiple myeloma that has come back or stopped responding to previous treatments. The study will evaluate whether this medication is safe and how well it works, either given on its own or combined with other established myeloma drugs. Researchers want to find the best dose and determine whether the treatment helps slow or control the cancer.

Multiple myeloma is a serious blood cancer that often returns or becomes resistant to standard treatments, leaving patients with limited options. This trial exists to explore whether this medication could offer a new, more effective approach for people whose myeloma has stopped responding to conventional therapies.